SFX by Ex Libris Inc.

Title:	Controversial cancer therapy finds political support
Source:	Science [0036-8075] Kaiser, J yr:2000

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Shirouzu, K. "Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case." Surgery today the japanese journal of surgery 33.6 (2003): 448-53.
description	2.	Burzynski, Stanislaw R. "The present state of antineoplaston research (1)." Integrative cancer therapies 3.1 (2004): 47-58.
description	3.	Burzynski, Stanislaw R. "Treatment of esthesioneuroblastoma and nonsmall cell lung cancer with phenylbutyrate.(Report)." Journal of cancer therapy 2.4 (2011): 518-.
description	4.	Glentzer, M. "Desperate measures. (cancer treatments administered by physician Stanislaw Burzynski)." Good housekeeping 222.1 (1996): 84-.
description	5.	"Lessons from antineoplaston." The Lancet 349.9054 (1997): 741-741.
description	6.	Burzynski, Stanislaw R. "Gene silencing--a new theory of aging." Medical hypotheses 60.4 (2003): 578-83.
description	7.	Block, Keith I. "Antineoplastons and the challenges of research in integrative care." Integrative cancer therapies 3.1 (2004): 3-4.
description	8.	Ono, N. "B-Flow contrast US with Levovist in hepatic tumors: preliminary results." The Kurume Medical Journal (2003): 21-5.
description	9.	Chowdhry, V. "Long-term survival in a patient with metastatic oropharynx squamous cell carcinoma to liver." Journal of Cancer Research and Therapeutics 8.1 (2012): 138-141.
description	10.	Farrow, B. "Butyrate inhibits pancreatic cancer invasion." Journal of gastrointestinal surgery 7.7 (2003): 864-870.
description	11.	"Antineoplastons." Ca 33.1 (1983): 57-9.
description	12.	Figg, J C D. "Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma." Mayo Clinic Proceedings 74.2 (1999): 137-45.
description	13.	Smith, Murray E. "The Burzynski Controversy in the United States and in Canada: A Comparative Case Study in the Sociology of Alternative Medicine." Canadian journal of sociology 17.2 (1992): 133-160.
description	14.	Hammer, Wayne B R. "Managing social conflict in complementary and alternative medicine research: the case of antineoplastons." Integrative cancer therapies 3.1 (2004): 59-65.
description	15.	Patterson, Ruth E E. "Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs." The journal of alternative and complementary medicine 8.4 (2002): 477-485.
description	16.	ASHCRAFT, C. "Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma." Integrative cancer therapies 5.1 (2006): 40-7.
description	17.	Decker, G M. "Pharmacologic and biologic therapies in cancer care: Part II." Clinical Journal of Oncology Nursing (2000): 283-4.
description	18.	Gunduz, M. "DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients." Medical hypotheses 63.4 (2004): 684-7.
description	19.	Murray, B. "Doctor of last resort." U.S. News & World Report 122.22 (1997): 18-18.
description	20.	"Émile Durkheim and the State." Revista Mediações / 25.1: 94-111.